Clinical Trial Update: Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pulsed, inhaled nitric oxide vs placebo in symptomatic pulmonary arterial hypertension was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• pulsed inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: Bellerophon Pulse Technologies | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2023-01-25